文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

评估循环蛋白与蛋白比值对肝细胞癌发病风险的因果效应。

Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.

作者信息

Yue Qiuyuan, Li Xiaoxia, Wan Xiaoye, Lin Xi, Li Yueming, Zhang Mingwei, Xu Shaohua

机构信息

Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.

Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

出版信息

Cancer Med. 2025 Jan;14(1):e70570. doi: 10.1002/cam4.70570.


DOI:10.1002/cam4.70570
PMID:39778021
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11705445/
Abstract

OBJECTIVE: Several observational studies have identified an association between plasma proteins and hepatocellular carcinoma (HCC). This study aimed to explore the potential causal relationship between the circulating protein-to-protein ratio and the morbidity risk of HCC. METHODS: Genetic association data for circulating plasma proteins and 2821 protein-to-protein ratios were sourced from the UKB PPP and Suhre's study. Genetic association data for HCC were sourced from the FinnGen cohort (finngen-R11-HCC) and the IEU OpenGWAS project (ieu-b-4953). Subsequently, a two-sample Mendelian randomization (MR) and drug-targeted MR approach were used to evaluate causality associations. To bolster the robustness of our findings, we conducted a series of sensitivity analyses. RESULTS: Eight protein-protein pairs were identified as causal factors for HCC in the two independent cohorts. For each standard deviation increase in protein-protein pair expression, susceptibility to HCC fluctuated from 0.4974 (95% confidence interval [CI]: 0.2506-0.9871) for the LAT2/SPRY2 protein pair to 1.9763 (95% CI: 1.3009-3.0026) for the ERBIN/LAT2 protein pair. However, among the significant protein pairs, only one circulating protein, TDRKH (odds ratio: 0.5964, 95% CI: 0.4196-0.8476), was causally associated with HCC. CONCLUSION: Using multiple datasets and methods, eight protein-protein pairs were identified as having causal associations with HCC. Protein-protein interactions can provide meaningful findings beyond simple pQTL analysis.

摘要

目的:多项观察性研究已确定血浆蛋白与肝细胞癌(HCC)之间存在关联。本研究旨在探讨循环蛋白与蛋白比值与HCC发病风险之间的潜在因果关系。 方法:循环血浆蛋白和2821种蛋白与蛋白比值的基因关联数据来自英国生物银行血浆蛋白质组计划(UKB PPP)和苏雷的研究。HCC的基因关联数据来自芬兰基因队列(finngen-R11-HCC)和IEU OpenGWAS项目(ieu-b-4953)。随后,采用两样本孟德尔随机化(MR)和药物靶向MR方法来评估因果关联。为加强研究结果的稳健性,我们进行了一系列敏感性分析。 结果:在两个独立队列中,确定了八对蛋白-蛋白对为HCC的因果因素。蛋白-蛋白对表达每增加一个标准差,HCC易感性波动范围为:LAT2/SPRY2蛋白对为0.4974(95%置信区间[CI]:0.2506 - 0.9871),ERBIN/LAT2蛋白对为1.9763(95%CI:1.3009 - 3.0026)。然而,在显著的蛋白对中,只有一种循环蛋白TDRKH(优势比:0.5964,95%CI:0.4196 - 0.8476)与HCC存在因果关联。 结论:使用多个数据集和方法,确定了八对蛋白-蛋白对与HCC存在因果关联。蛋白-蛋白相互作用能提供超越简单蛋白质定量性状位点(pQTL)分析的有意义发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/8c3f0e4b3af3/CAM4-14-e70570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/a86969a15d45/CAM4-14-e70570-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/8a81bfb9fe54/CAM4-14-e70570-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/9c26610ee699/CAM4-14-e70570-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/f293345c39ec/CAM4-14-e70570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/8c3f0e4b3af3/CAM4-14-e70570-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/a86969a15d45/CAM4-14-e70570-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/8a81bfb9fe54/CAM4-14-e70570-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/9c26610ee699/CAM4-14-e70570-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/f293345c39ec/CAM4-14-e70570-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f16c/11705445/8c3f0e4b3af3/CAM4-14-e70570-g002.jpg

相似文献

[1]
Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.

Cancer Med. 2025-1

[2]
Causality of blood metabolites on hepatocellular carcinoma and cholangiocarcinoma: a metabolome-wide mendelian randomization study.

BMC Cancer. 2025-3-4

[3]
Causal associations between platelet count, alcohol consumption, and the risk of liver hepatocellular carcinoma based on a Mendelian randomization study.

Front Endocrinol (Lausanne). 2024

[4]
Enhanced circulating transforming growth factor beta 1 is causally associated with an increased risk of hepatocellular carcinoma: a mendelian randomization meta-analysis.

Oncotarget. 2016-12-20

[5]
Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.

Genes (Basel). 2024-9-9

[6]
Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.

J Cancer Res Clin Oncol. 2024-10-22

[7]
Potential functions and causal associations of VPS29 in hepatocellular carcinoma: a bioinformatic and Mendelian randomization study.

Eur Rev Med Pharmacol Sci. 2023-10

[8]
[Causal relationship between ferroptosis-related gene HSPA5 and hepatocellular carcinoma: a study based on mendelian randomization and mediation analysis].

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024-12-25

[9]
Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study.

BMC Cancer. 2024-7-10

[10]
Low-density lipoprotein cholesterol and risk of hepatocellular carcinoma: a Mendelian randomization and mediation analysis.

Lipids Health Dis. 2023-7-31

引用本文的文献

[1]
Genetic evidence for causal effects of inflammatory protein factors on breast cancer.

Discov Oncol. 2025-8-7

本文引用的文献

[1]
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.

J Hepatol. 2025-3

[2]
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.

J Hepatol. 2025-1

[3]
Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance.

Ann Surg. 2024-9-1

[4]
Expanding Selection Criteria in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Long-term Follow-up of a National Registry and 2 Transplant Centers.

Transplantation. 2024-12-1

[5]
ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression.

Nat Commun. 2024-5-31

[6]
IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway.

Cell Death Discov. 2024-5-13

[7]
Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.

Cell Biol Int. 2024-5

[8]
Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions.

Cell Genom. 2024-3-13

[9]
Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience.

Int J Surg. 2024-5-1

[10]
Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT-PD-L1 Axis.

Adv Sci (Weinh). 2024-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索